Researchers from CNAG-CRG and IRB Barcelona contribute to the description of the most comprehensive map of cancer genomes Blog Post

The international team of scientists of the ‘Pan-Cancer Analysis of Whole Genomes Project’ (PCAWG) today published 23 studies in the Nature journals, describing the most comprehensive map of cancer genomes from 38 types of tumours to date. Among the 1,300 researchers who have contributed to the project are scientists from the Institute for Research in Biomedicine (IRB Barcelona) and the Centro Nacional de Análisis Genómico (CNAG-CRG) in the Barcelona Science Park.The results are an important step for the development of personalised medicine to treat cancer.


Núria López-Bigas receives the National ‘Doctores Diz Pintado’ Cancer Research Prize Blog Post

Núria López-Bigas, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) in the Barcelona Science Park, has received the IX National ‘Doctores Diz Pintado’ Cancer Research Prize for her career path. The researcher is the first female scientist to be presented with this prize, which is presented every year by the Fundación de Investigación del Cáncer de la Universidad de la Salamancaa (FICUS)-Centro de Investigación del Cáncer (USAL-CSIC)  to promote and acknowledge the contribution of young Spanish researchers to Cancer Research.


Esteve acquires German pharmaceutical company Riemser and expands its presence in Europe Blog Post

Esteve have come to an agreement to acquire the German pharmaceutical company Riemser. Headquartered in Berlin, Riemser has subsidiaries in the United Kingdom, France, and Spain and is present in nearly 50 countries through alliances with third parties. This acquisition provides Esteve ––which has its Drug Discovery and Preclinical Development Center at the Barcelona Science Park–– with greater pharmaceutical presence in Europe’s main markets and a portfolio of proprietary specialty products for hospital use. 


Researchers from the CNAG-CRG develop a new classification system for tumours Blog Post

Based on the largest study of cancer patients of its kind, scientists at the Centre Nacional d’Anàlisi Genòmica (CNAG-CRG), located in the Barcelona Science Park, have created a new way of classifying tumours. Clinicians can use genome sequencing to assign their patients’ tumours to one of sixteen groups in the new classification system, ten of which provide important information for the diagnosis and treatment of the disease, like whether an individual will respond to immunotherapy. The work is published in PLOS Computational Biology.


Aerie Pharmaceuticals announces agreement to acquire Avizorex Pharma for $10 Million Blog Post

La farmacèutica Aerie Pharmaceuticals, que cotitza al Nasqad, ha annunciat l’adquisició d’Avizorex Pharma (AVX Pharma), amb seu al Parc Científic de Barcelona, per un import de 10 millones de dòlares. La companyia, fundada l’any 2013 com a spin-off de la Universitat Miguel Hernandez de Elche (UMH) per l’emprenedor Patrick Tresserras i el professor Carlos Belmonte de l’Institut de Neurociencias (UMH -CSIC), està especialitzada en el desenvolupament de teràpies innovadores per a la síndrome d’ull sec.


Salvador Aznar Benitah receives the “Premio Fundación Carmen y Severo Ochoa 2019” Blog Post

Salvador Aznar Benitah, ICREA at the Institute for Research in Biomedicine (IRB Barcelona) in the Barcelona Science Park, as received the “Premio Carmen y Severo Ochoa de Investigación en Biología Molecular” in acknowledgement of his work on adult stem cells and the relation of these with circadian rhythms and metastasis, and also in recognition of his recent entrepreneurial activity as co-founder of Ona Therapeutics.


IBEC presents its capabilities in 3D bioprinting at the 4th edition of INDUSTRY Blog Post

The Institute for Bioengineering of Catalonia (IBEC), based in the Barcelona Science Park, participated in the fourth edition of INDUSTRY From Needs to Solutions, which took place from 29th to 31st October at Fira Barcelona´s Gran Via venue. The event brought together more than 150 companies in its exhibition area and 150 speakers within the framework of Barcelona Industry Week, that brought together seven major events related to digital transformation at Fira Barcelona. IoT Solutions World Congress, Blockchain Solutions World and AI & Cognitive Systems Forum were other events that added to this great summit where the achievements and innovations of disruptive technologies in the field of health became evident.


Scientists build machine learning-based algorithm to predict which cancer patients benefit from immunotherapy Blog Post

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) in the Barcelona Science Park, in collaboration with the Centre for Genomic Regulation (CRG) and Radboud University, have built a tool that detects genetic mutations that trigger the immune system, helping identify which cancer patients are more likely to benefit from immunotherapy. The algorithm also reveals which people living with hereditary diseases may benefit from drugs that already exist. The new technology’s potential is described today in Nature Genetics.


GlyCardial begins the clinical trial of its novel diagnostic device for myocardial ischemia Blog Post

GlyCardial Diagnostics, located at the Barcelona Science Park, has announced the enrolment of the first two patients in the EDICA trial: a multicenter international clinical study for the early detection of myocardial ischaemia. The company –a spinoff of the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR-HSCSP) and the Spanish National Research Council (CSIC), has developed innovative technology for the detection of Apo J-Glyc protein, as a novel biomarker in blood for the diagnosis and prognosis of myocardial ischemia, and expects to demonstrate the reliability of the new test in hospital laboratories.